Medication info
Pregabacon 150 mg (Pregabalin)

Pregabacon 150 mg (Pregabalin)

Prescription medicationHard capsuleOral
Ingredient · strength
Pregabalin›150mg / 1 capsule
Manufacturer / importer
CTC Bio Co., Ltd.
Appearance
White hard gelatin capsule containing white powder
Packaging
30 capsules per bottle, 60 capsules per bottle
Approval status
Active

MFDS item code 201702684 · Approved 2017.05.29 · Insurance code 669502180

Summary

Main use
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial seizures in epilepsy
Who takes it
Adults · Children
Adult dose
This medication is administered orally as pregabalin, with the total daily dose divided into 2 doses, regardless of food. Since this medication is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See “5. Patients with Renal Impairment”) 1. Neuropathic Pain 1) Peripheral Neuropathic Pain Adults: This medication may be administered at an initial dose of 150 mg/day. Based on each patient’s response and tolerability, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 2) Central Neuropathic Pain Adults: This medication may be administered at an initial dose of 150 mg/day. Based on each patient’s response and tolerability, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See “4. Discontinuation of Treatment”) 2. Epilepsy Adults: This medication may be administered at an initial dose of 150 mg/day. Based on each patient’s response and tolerability, the dose may be increased to 300 mg/day after 1 week. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medication for fibromyalgia is 300 mg-450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased to 150 mg twice daily (300 mg/day) within 1 week. For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased to 225 mg twice daily (450 mg/day) within 1 week. Clinical studies were also conducted at a dose of 600 mg/day; however, there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of Treatment Based on current clinical experience, if treatment with this medication is discontinued, it should be withdrawn gradually over at least 1 week. 5. Patients with Renal Impairment After entering the systemic circulation, this medication is primarily excreted by the kidneys unchanged. Since the clearance of this medication is directly affected by creatinine clearance, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the formula below. This medication is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered promptly after each 4-hour hemodialysis session. [Table 1]. Pregabalin Dosage Based on Renal Function Creatinine clearance (CLcr), (mL/min) ≥60: Initial dose 150 (mg/day), maximum dose 600 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥30-<60: Initial dose 75 (mg/day), maximum dose 300 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥15-<30: Initial dose 25-50 (mg/day), maximum dose 150 (mg/day), QD or BID Creatinine clearance (CLcr), (mL/min) <15: Initial dose 25 (mg/day), maximum dose 75 (mg/day), QD Supplemental dose after hemodialysis: 25, 100, single dose b TID = total daily dose administered in 3 divided doses BID = total daily dose administered in 2 divided doses QD = administered once daily a: The total daily dose (mg/day) should be divided as specified under the method of administration. b: A supplemental dose refers to an additional dose administered once. 6. Patients with Hepatic Impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Elderly Patients (65 years and older) Dose reduction may be necessary in elderly patients with impaired renal function.
Child dose
Administration is not recommended for children under 12 years of age or adolescent patients aged 12-17 years because there are insufficient data on safety and efficacy.

Ingredients

Manufacturer
CTC Bio Co., Ltd.

Efficacy & effects

Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial seizures in epilepsy

  • Peripheral neuropathic pain
  • central neuropathic pain
  • partial seizures
  • fibromyalgia
View approved original text

This medication is used to treat peripheral and central neuropathic pain in adults and serves as an adjunct for partial seizures in epilepsy. It is also effective for the treatment of fibromyalgia. It is mainly used to improve neurologically related pain and seizure symptoms.

How to take

Adult dose

This medication is administered orally as pregabalin, with the total daily dose divided into 2 doses, regardless of food. Since this medication is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See “5. Patients with Renal Impairment”) 1. Neuropathic Pain 1) Peripheral Neuropathic Pain Adults: This medication may be administered at an initial dose of 150 mg/day. Based on each patient’s response and tolerability, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 2) Central Neuropathic Pain Adults: This medication may be administered at an initial dose of 150 mg/day. Based on each patient’s response and tolerability, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See “4. Discontinuation of Treatment”) 2. Epilepsy Adults: This medication may be administered at an initial dose of 150 mg/day. Based on each patient’s response and tolerability, the dose may be increased to 300 mg/day after 1 week. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medication for fibromyalgia is 300 mg-450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased to 150 mg twice daily (300 mg/day) within 1 week. For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased to 225 mg twice daily (450 mg/day) within 1 week. Clinical studies were also conducted at a dose of 600 mg/day; however, there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of Treatment Based on current clinical experience, if treatment with this medication is discontinued, it should be withdrawn gradually over at least 1 week. 5. Patients with Renal Impairment After entering the systemic circulation, this medication is primarily excreted by the kidneys unchanged. Since the clearance of this medication is directly affected by creatinine clearance, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the formula below. This medication is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered promptly after each 4-hour hemodialysis session. [Table 1]. Pregabalin Dosage Based on Renal Function Creatinine clearance (CLcr), (mL/min) ≥60: Initial dose 150 (mg/day), maximum dose 600 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥30-<60: Initial dose 75 (mg/day), maximum dose 300 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥15-<30: Initial dose 25-50 (mg/day), maximum dose 150 (mg/day), QD or BID Creatinine clearance (CLcr), (mL/min) <15: Initial dose 25 (mg/day), maximum dose 75 (mg/day), QD Supplemental dose after hemodialysis: 25, 100, single dose b TID = total daily dose administered in 3 divided doses BID = total daily dose administered in 2 divided doses QD = administered once daily a: The total daily dose (mg/day) should be divided as specified under the method of administration. b: A supplemental dose refers to an additional dose administered once. 6. Patients with Hepatic Impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Elderly Patients (65 years and older) Dose reduction may be necessary in elderly patients with impaired renal function.

Child dose

Administration is not recommended for children under 12 years of age or adolescent patients aged 12-17 years because there are insufficient data on safety and efficacy.

Precautions

This medication may increase the risk of suicidal thoughts or behavior, and patients should be closely monitored for symptoms of depression or mood changes during use. Patients with hypersensitivity to this drug or specific inherited lactose intolerance disorders should not take this medication. For diabetic patients, dose adjustments for blood sugar control medications may be necessary due to potential weight gain. If signs of allergic reactions such as angioedema occur, this medication should be discontinued immediately. Elderly patients should take special care when starting this medication to avoid risks of falls due to dizziness or drowsiness. Any occurrence of blurred vision or visual changes should be discussed with a healthcare provider. Abrupt discontinuation of this medication may result in withdrawal symptoms such as insomnia, headache, and anxiety, so it should be tapered off gradually under the guidance of a healthcare provider. Patients with a history of substance abuse may have a higher risk of abuse with this medication and should be closely monitored. Patients with impaired kidney function may require dose adjustments. Patients with cardiovascular disease must be carefully monitored during administration of this drug. When combined with opioid analgesics, the risk of central nervous system depression is increased, so caution is necessary. This medication may cause dizziness and drowsiness, so patients should check their condition before driving or operating dangerous machinery. In the early stages of pregnancy, there is a risk of congenital malformations in the fetus, so pregnant women should avoid taking this medication, and women of childbearing age should use effective contraception. Breastfeeding women should discuss with their healthcare provider as this medication may be transferred to breast milk. Overdose may cause symptoms such as confusion, drowsiness, and depression, and may require treatment such as dialysis if necessary. Keep this medication out of the reach of children and avoid transferring it to other containers.

Side effects

  • Suicidal impulses
  • suicidal behavior
  • depression
  • abnormal changes in mood and behavior
  • angioedema
  • facial swelling
  • periorbital swelling
  • upper respiratory swelling
  • dizziness
  • drowsiness
Show 203 more
  • loss of consciousness
  • confusion
  • mental disorders
  • blurred vision
  • vision changes
  • insomnia
  • headache
  • nausea
  • anxiety
  • diarrhea
  • influenza-like syndrome
  • restlessness
  • sadness
  • suicidal thoughts
  • pain
  • seizures
  • sweating
  • misuse
  • abuse
  • dependence
  • congestive heart failure
  • severe respiratory depression
  • respiratory function impairment
  • respiratory diseases
  • neurological disorders
  • kidney disorders
  • rhinitis
  • neutropenia
  • increased appetite
  • decreased appetite
  • hypoglycemia
  • confusion
  • disorientation
  • irritability
  • euphoria
  • decreased libido
  • depersonalization
  • sexual paresthesia
  • restlessness
  • agitation
  • mood swings
  • emotional blunting
  • emotional elevation
  • hallucinations
  • abnormal dreams
  • increased libido
  • panic attacks
  • loss of inhibition
  • apathy
  • dizziness
  • drowsiness
  • ataxia
  • motor coordination disturbance
  • balance disorders
  • amnesia
  • attention disorders
  • memory disorders
  • tremors
  • dysarthria
  • sensory disturbances
  • sensory loss
  • sedation
  • hypersomnia
  • cognitive impairment
  • nystagmus
  • speech disorders
  • myoclonus
  • diminished reflexes
  • motor disturbances
  • psychomotor agitation
  • positional vertigo
  • hypersensitivity
  • burning sensation
  • action tremors
  • fainting
  • confusion
  • motor retardation
  • olfactory disturbances
  • taste loss
  • writing disabilities
  • blurred vision
  • double vision
  • peripheral vision loss
  • visual field defects
  • photophobia
  • dry eyes
  • eye swelling
  • vision loss
  • eye pain
  • eye fatigue
  • increased tear production
  • eye irritation
  • mydriasis
  • vibration sensation
  • changes in depth perception
  • strabismus
  • brightness of vision
  • dizziness
  • auditory hypersensitivity
  • first-degree atrioventricular block
  • tachycardia
  • sinus bradycardia
  • sinus tachycardia
  • sinus arrhythmia
  • hypotension
  • hypertension
  • flushing
  • facial flushing
  • peripheral coldness
  • dyspnea
  • epistaxis
  • cough
  • nasal congestion
  • rhinitis
  • snoring
  • throat tension
  • nasal dryness
  • respiratory depression
  • vomiting
  • abdominal distension
  • constipation
  • dry mouth
  • bloating
  • excessive salivation
  • gastroesophageal reflux
  • oral sensory loss
  • ascites
  • dysphagia
  • pancreatitis
  • sweating
  • papular rash
  • urticaria
  • cold sweats
  • muscle cramps
  • arthralgia
  • back pain
  • limb pain
  • cervical cramps
  • joint swelling
  • myalgia
  • muscle spasms
  • neck pain
  • muscle rigidity
  • rhabdomyolysis
  • voiding disorders
  • urinary incontinence
  • reduced urination
  • renal failure
  • erectile dysfunction
  • delayed ejaculation
  • sexual dysfunction
  • dysmenorrhea
  • amenorrhea
  • mastalgia
  • breast discharge
  • gynecomastia
  • peripheral edema
  • edema
  • gait disturbances
  • falls
  • feeling of intoxication
  • paresthesia
  • fatigue
  • chest tightness
  • generalized edema
  • pain
  • fever
  • chills
  • weakness
  • thirst
  • weight gain
  • increased alanine aminotransferase
  • increased serum creatine phosphokinase
  • increased aspartate aminotransferase
  • increased blood sugar
  • decreased platelet count
  • decreased serum potassium
  • weight loss
  • increased serum creatinine
  • decreased white blood cell count
  • hypersensitivity
  • allergic reaction
  • headache
  • keratitis
  • pulmonary edema
  • nausea
  • diarrhea
  • tongue swelling
  • itching
  • Stevens-Johnson syndrome
  • toxic epidermal necrolysis
  • urinary retention
  • gynecomastia
  • lethargy
  • delirium
  • paralysis (facial paralysis)
  • affective disorder
  • drowsiness
  • state of confusion
  • depression
  • agitation
  • restlessness
  • seizures

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to keep it protected from air and moisture, and it is best kept at room temperature between 15 to 30 degrees Celsius. Proper storage will help maintain the medication's effectiveness.

Appearance and packaging

Appearance

White hard gelatin capsule containing white powder

Package unit

30 capsules per bottle, 60 capsules per bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.